Cholangiocarcinoma imaging: from diagnosis to response assessment
- PMID: 38578323
- DOI: 10.1007/s00261-024-04267-y
Cholangiocarcinoma imaging: from diagnosis to response assessment
Abstract
Cholangiocarcinoma (CCA), a highly aggressive primary liver cancer arising from the bile duct epithelium, represents a substantial proportion of hepatobiliary malignancies, posing formidable challenges in diagnosis and treatment. Notably, the global incidence of intrahepatic CCA has seen a rise, necessitating a critical examination of diagnostic and management strategies, especially due to presence of close imaging mimics such as hepatocellular carcinoma (HCC) and combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). Hence, it is imperative to understand the role of various imaging modalities such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), elucidating their strengths, and limitations in diagnostic precision and staging accuracy. Beyond conventional approaches, there is emerging significance of functional imaging tools including positron emission tomography (PET)-CT and diffusion-weighted (DW)-MRI, providing pivotal insights into diagnosis, therapeutic assessment, and prognostic evaluation. This comprehensive review explores the risk factors, classification, clinical features, and role of imaging in the holistic spectrum of diagnosis, staging, management, and restaging for CCA, hence serving as a valuable resource for radiologists evaluating CCA.
Keywords: Abdominal imaging; Cholangiocarcinoma (CCA); Computed tomography (CT); Treatment response assessment.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.J Formos Med Assoc. 2020 Jan;119(1 Pt 1):125-133. doi: 10.1016/j.jfma.2019.02.012. Epub 2019 Mar 12. J Formos Med Assoc. 2020. PMID: 30876788
-
Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.Liver Int. 2019 Dec;39(12):2386-2396. doi: 10.1111/liv.14261. Epub 2019 Oct 20. Liver Int. 2019. PMID: 31544304
-
Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.Radiol Oncol. 2020 May 28;54(2):149-158. doi: 10.2478/raon-2020-0029. Radiol Oncol. 2020. PMID: 32463393 Free PMC article.
-
Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.Korean J Radiol. 2020 Oct;21(10):1115-1125. doi: 10.3348/kjr.2020.0091. Epub 2020 Jul 27. Korean J Radiol. 2020. PMID: 32729276 Free PMC article. Review.
-
Clinical presentation, diagnosis and staging of cholangiocarcinoma.Liver Int. 2019 May;39 Suppl 1:98-107. doi: 10.1111/liv.14086. Epub 2019 Mar 25. Liver Int. 2019. PMID: 30831002 Review.
Cited by
-
Misdiagnosis Based on Neoplastic Markers-Extremely High Alpha-Fetoprotein in Patients with Intrahepatic Cholangiocarcinoma with Literature Review of the Published Cases.Medicina (Kaunas). 2024 Jul 9;60(7):1109. doi: 10.3390/medicina60071109. Medicina (Kaunas). 2024. PMID: 39064538 Free PMC article. Review.
-
Prognostic Impact of CCA Components in Combined Hepatocellular Carcinoma-Cholangiocarcinoma.J Hepatocell Carcinoma. 2024 Dec 18;11:2483-2492. doi: 10.2147/JHC.S491243. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39712948 Free PMC article.
-
Superficial Vein Thrombosis in an Asymptomatic Case of Cholangiocarcinoma with Recent History of COVID-19.Life (Basel). 2024 Aug 30;14(9):1095. doi: 10.3390/life14091095. Life (Basel). 2024. PMID: 39337879 Free PMC article.
-
Progress in the application of fludeoxyglucose positron emission tomography computed tomography in biliary tract cancer.World J Hepatol. 2025 May 27;17(5):105446. doi: 10.4254/wjh.v17.i5.105446. World J Hepatol. 2025. PMID: 40501462 Free PMC article. Review.
References
-
- Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005 Oct 8;366(9493):1303–14. doi: https://doi.org/10.1016/S0140-6736(05)67530-7 . Erratum in: Lancet. 2006 May 20;367(9523):1656. PMID: 16214602.
-
- Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014 Jun 21;383(9935):2168–79. doi: https://doi.org/10.1016/S0140-6736(13)61903-0 . Epub 2014 Feb 26. PMID: 24581682; PMCID: PMC4069226.
-
- Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013 Jan;11(1):13–21.e1; quiz e3–4. doi: https://doi.org/10.1016/j.cgh.2012.09.009 . Epub 2012 Sep 13. PMID: 22982100; PMCID: PMC3596004.
-
- Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011 Jul;54(1):173–84. doi: https://doi.org/10.1002/hep.24351 . PMID: 21488076; PMCID: PMC3125451.
-
- Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004 Mar;40(3):472–7. doi: https://doi.org/10.1016/j.jhep.2003.11.030 . PMID: 15123362.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical